Clinical trials: Treatment-Resistant
Tuberculosis, Multidrug-Resistant
Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)
This study is to evaluate the effectiveness and safety of a 9-month MDR-END regimen as a treatment for fluoroquinolone-sensitive multidrug resistant pulmonary tuberculosis in the real-world clinical setting.
- Trial name
- NCT06674291
- Testing
- No intervention (observational study)
- Volunteers
- 222 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder, Treatment Resistant Depression
An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients
The TARGET study is an active-controlled evaluation of AXS-05 compared to bupropion in patients with treatment-resistant major depressive disorder (MDD) who are adherent to study drug.
- Trial name
- TARGET (NCT04971291)
- Testing
- AXS-05, Bupropion SR
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Axsome Therapeutics, Inc.
Prostatic Neoplasm
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
This Phase 1/2 study is intended to investigate the safety, tolerability, and radiation dosimetry of 177Lu-PSMA-R2 and further assess preliminary efficacy data in patients with metastatic castration-resistant prostate cancer…
- Trial name
- PROter (NCT03490838)
- Testing
- 177Lu-PSMA-R2
- Where
- 11 sites in United States, Spain
- Volunteers
- 27 people
- Sponsor
- Advanced Accelerator Applications
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
This study is to evaluate the safety, and preliminary antitumor activity of TY-302 combined with Abiraterone tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
- Trial name
- NCT07104617
- Testing
- TY-302, Abiraptor
- Where
- China
- Volunteers
- 48 people
- Sponsor
- TYK Medicines, Inc
Hypertension, Metabolic Syndrome X
Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities
The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome.
- Trial name
- NCT00242814
- Testing
- Micardis, Amlodipine, Abdominal biopsy
- Where
- 31 sites in France
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Human Immunodeficiency Virus
Kaletra: Therapy With Double Protease Inhibitors
Therapy with lopinavir/ritonavir (Kaletra) and one other protease inhibitor in Human Immunodeficiency Virus participants
- Trial name
- NCT01075191
- Where
- 17 sites in Germany
- Volunteers
- 65 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Focal Epilepsy
A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy
The main purpose of this study is to investigate effects of Lu AG06466 on seizure activity after increasing daily doses during 4 weeks in participants with an implanted responsive neurostimulation system.
- Trial name
- NCT05081518
- Testing
- Lu AG06466
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lundbeck A/S
Small Cell Lung Cancer, Gastric Adenocarcinoma
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
- Conditions
- Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma
- Trial name
- NCT03365791
- Testing
- PDR001, LAG525
- Where
- 20 sites in United States
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
A Phase 2 study investigating the efficacy and safety of ONCOS-102 alone or in combination with balstilimab (a programmed death receptor-1 [PD-1] inhibitor).
- Trial name
- NCT05561491
- Testing
- ONCOS-102, Balstilimab
- Sponsor
- Targovax Oy
Multiple Myeloma
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to determine the maximum tolerated dose (MTD) of pomalidomide in combination with bortezomib and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma
- Trial name
- NCT01497093
- Testing
- Pomalidomide, Bortezomib, Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Celgene
HIV Infections
Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)
The primary objective of this trial was to assess the presence of susceptibility to tipranavir and other ARVs of the HIV-1 isolates in treatment experienced patients.
- Trial name
- NCT00615563
- Testing
- NO BI Drug administered
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 246 people
- Sponsor
- Boehringer Ingelheim
COPD, Chronic Obstructive Pulmonary Disease
A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD
To assess the effect of treatment with Glycopyronnium (GP) MDI administered twice daily (BID) and Formoterol Fumarate (FF) MDI administered BID on specific image-based airway volumes and resistance in subjects with moderate to…
- Trial name
- NCT02937584
- Testing
- GP MDI (PT001) 14.4 μg, FF MDI (PT005) 9.6 μg
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Pearl Therapeutics, Inc.
Non-metastatic Castration-resistant Prostate Cancer
An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings
This is an observational study in which patient data from the past on men with non-metastatic castration-resistant prostate cancer are studied.
- Trial name
- DEAR (NCT05362149)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Enzalutamide, Apalutamide
- Where
- United States
- Volunteers
- 870 people
- Sponsor
- Bayer
Invasive Mold Infections
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
The purpose of this study is to evaluate the efficacy and safety of fosmanogepix (administered IV or oral) for the treatment of adult patients with invasive mold infections.
- Trial name
- NCT06925321
- Testing
- Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet
- Where
- 90 sites in United States, Australia and 13 more
- Volunteers
- 234 people
- Sponsor
- Basilea Pharmaceutica
Metastatic Prostate Cancer
One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™
This is an open-label, single-arm, multi-center extension study to evaluate safety in patients with mCRPC of YONSA 500 mg (4 x 125 mg qd) with methylprednisolone (4 mg bid).
- Trial name
- NCT02962284
- Testing
- abiraterone acetate with Methylprednisolone
- Volunteers
- 20 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Papular-pustular Rosacea
Isotretinoin in Papular-Pustular Rosacea
A national, multicentre, prospective, randomised, double-blind, phase III study in 2 parallel groups of isotretinoin versus placebo in patients presenting papular-pustular rosacea resistant to standard therapy.
- Trial name
- ISOROS (NCT00882531)
- Testing
- isotretinoin
- Volunteers
- 156 people
- Sponsor
- Laboratoires Bailleul-Biorga
Castration-Resistant Prostatic Cancer
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
- Trial name
- MAGNITUDE (NCT03748641)
- Testing
- Niraparib, Abiraterone Acetate, Prednisone
- Where
- 318 sites in United States, Argentina and 27 more
- Volunteers
- 765 people
- Sponsor
- Janssen Research & Development, LLC
Polycythemia Vera
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
The purpose of this open-label, single arm, multi-center Expanded Treatment Protocol (ETP) was to provide early access to ruxolitinib and evaluate safety information in patients with polycythemia vera (PV) who were hydroxyurea…
- Trial name
- NCT02292446
- Testing
- Ruxolitinib
- Where
- 65 sites in Austria, Belgium and 10 more
- Volunteers
- 161 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus Type 2
Lispro Mix 25 vs. Glargine in Type 2 Diabetics
In patients with type 2 diabetes who have not been on insulin therapy before the study will achieve better glycemic control by the treatment regiment consisting of two times daily insulin lispro mix 25 than by the treatment…
- Trial name
- IOOL (NCT00551356)
- Testing
- Insulin lispro mix 25, Glargine
- Where
- Mexico
- Volunteers
- 53 people
- Sponsor
- Eli Lilly and Company
MRSA Bloodstream Infection, MRSA Bacteremia
Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia
This is an open-label, expanded access study of exebacase used in addition to antistaphylococcal antibiotics in adult patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI)…
- Conditions
- MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis, Covid19
- Trial name
- NCT04597242
- Testing
- Exebacase
- Where
- 2 sites in United States
- Sponsor
- ContraFect